Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Cash (2019 - 2025)

Historic Change in Cash for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $3.3 million.

  • Keros Therapeutics' Change in Cash fell 9739.56% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.8 million, marking a year-over-year decrease of 3301.68%. This contributed to the annual value of $229.0 million for FY2024, which is 34056.06% up from last year.
  • Latest data reveals that Keros Therapeutics reported Change in Cash of $3.3 million as of Q3 2025, which was down 9739.56% from -$30.3 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Change in Cash peaked at $160.6 million during Q1 2025, and registered a low of -$36.6 million during Q2 2024.
  • Its 5-year average for Change in Cash is $22.6 million, with a median of $3.3 million in 2025.
  • Over the last 5 years, Keros Therapeutics' Change in Cash had its largest YoY gain of 507122.25% in 2023, and its largest YoY loss of 24386.89% in 2023.
  • Over the past 5 years, Keros Therapeutics' Change in Cash (Quarter) stood at $8.7 million in 2021, then skyrocketed by 355.84% to $39.6 million in 2022, then rose by 9.17% to $43.3 million in 2023, then tumbled by 32.38% to $29.2 million in 2024, then plummeted by 88.86% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, -$30.3 million for Q2 2025, and $160.6 million during Q1 2025.